ICLR vs TECH
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
ICLR presents a stark contrast between strong deterministic health and deteriorating growth fundamentals. While the Piotroski F-Score of 7/9 indicates a strong financial foundation and the stock trades below its Graham Number ($142.86) and Book Value (P/B 0.95), the recent earnings collapse (-98.7% YoY) is a critical concern. The massive PEG ratio of 19.29 suggests the stock is significantly overvalued relative to its current growth trajectory. Despite analyst 'Buy' recommendations, the technical trend remains bearish and revenue growth has stagnated.
Bio-Techne exhibits exceptional financial health with a Piotroski F-Score of 8/9 and a very low Debt/Equity ratio of 0.17. However, there is a massive disconnect between the current price ($60.58) and deterministic value metrics, such as the Graham Number ($12.40) and Intrinsic Value ($10.94). While the PEG ratio of 0.76 and forward P/E of 27.99 suggest growth potential that justifies a premium, stagnant revenue growth (-0.40%) and bearish technical trends temper the outlook. The stock is a high-quality company trading at a significant growth premium.
Compare Another Pair
Related Comparisons
ICLR vs TECH: Head-to-Head Comparison
This page compares ICON Public Limited Company (ICLR) and Bio-Techne Corporation (TECH) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.